Yea Christopher, chief development officer at KalVista Pharmaceuticals (KALV), has been a consistent seller of company stock over the past year, with no open-market purchases on record. Across 42 total Form 4 filings, all monetary activity has been on the sell side, totaling roughly $1.8 million. The most recent cluster of transactions came on June 11, 2026, when Christopher reported 11 separate dispositions (code D) of KALV shares, though each was valued at $0, indicating returns to the issuer rather than cash sales. The last actual open-market sale occurred on May 27, 2026, for approximately $905,000, the largest single transaction in the filing window.
The pattern shows a steady cadence of option exercises (code M) paired with same-day or next-day sales (code S), a common approach for converting vested equity into cash. On May 27, Christopher exercised options valued at roughly $239,000 and immediately sold shares worth about $905,000, suggesting a net cash-out of the position. Earlier in May, smaller sales of $52,645, $63,158, and $29,650 occurred on May 26, 22, and 18, respectively, each following option exercises. The selling continued through February 2026, with sales of $67,669 and $16,635, and stretched back to November 2025, when Christopher sold $58,256 worth of KALV stock.
The absence of any open-market purchases (code P) or acquisitions (code A) since the start of the filing period underscores a one-directional bias toward liquidation. While the June 11 dispositions carried no dollar value, they add to the volume of shares being shed, reinforcing a pattern of consistent, incremental divestment rather than any accumulation. The data offers no signal of buying conviction, with every monetary transaction over the past year representing a sale of KALV shares.
AI-assisted summary